Skip to main content
. 2019 Apr 12;11:3171–3185. doi: 10.2147/CMAR.S195424

Figure 2.

Figure 2

SLC5A1 blockade suppressed pancreatic cell growth. (A) The mRNA of SGLTs in pancreatic cancer Panc-1 cells. Only the mRNA level of SGLT1 (SLC5A1) and SMIT1 (SLC5A3) showed relative high level of expression in Panc-1 cells. (B) the mRNA expression and (C) the protein expression of SLC5A1 and SLC5A3 in different pancreatic cancer cell lines and normal pancreatic cancer cells. SLC5A1 but not SLC5A3 was overexpressed in pancreatic cancer cells compared to normal cells. (D) Expressions of SLC5A1 in Panc-1 and Panc-2 cells were silenced by shRNA and validated by qPCR and immunoblotting. (E) Panc-1 and Panc-2 cells transfected with shSLC5A1 or scramble control were seeded, and cell number was counted every two days for 10 days. Inhibition of SLC5A1 reduced pancreatic cell growth. A non-selective SGLT1 inhibitor phlorizin, showed similar effects to SLC5A1 knockdown. (F) Cell cycle distribution analysis of 72 hours-cultured Panc-1 and Panc-2 cells with or without SLC5A1 knockdown. Inhibition of SLC5A1 arrested the pancreatic cancer cell lines at G0/G1 phase. A non-selective SGLT1 inhibitor phlorizin, showed similar effects to SLC5A1 knockdown. (G) SLC5A1 knockdown Panc-1 and Panc-2 cells showed reduced clonogenic survival compared to control cells. A non-selective SGLT1 inhibitor phlorizin, showed similar effects to SLC5A1 knockdown. *P<0.05, **P<0.01, ***P<0.0001.